Standardised in vitro susceptibility testing of Borrelia burgdorferi against well-known and newly developed antimicrobial agents - Possible implications for new therapeutic approaches to lyme disease

International Journal of Medical Microbiology

Volumn 291, Issue SUPPL. 33, 2002, Pages 125-137

  Hunfeld, Klaus Peter ^a   Kraiczy, Peter ^a   Kekoukh, Elena ^a   Schäfer, Volker ^a   Brade, Volker ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

BACTERIAL COUNT; BORRELIA BURGDORFERI; DRUG EFFECT; HUMAN; LYME DISEASE; MICROBIOLOGICAL EXAMINATION; REVIEW; TIME; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BORRELIA BURGDORFERI; BORRELIA BURGDORFERI GROUP; COLONY COUNT, MICROBIAL; HUMANS; LYME DISEASE; MICROBIAL SENSITIVITY TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036066331     PISSN: 14384221     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1438-4221(02)80024-8     Document Type: Conference Paper

References (80)

1. Efficiacy of clarithromycin for treatment of experimental Lyme arthritis in vivo
2. In vitro susceptibility of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone
3. Efficiacy of vancomycin plus rifampin in experimental aortic valve endocarditis due to methicillin resistant Staphylococcus aureus: In vitro-in vivo correlations
4. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics
5. Isolation and characterisation of the Lyme disease spirochete from the skin of patients with erythema chronicum migrans
6. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: Influence of test conditions on minimal inhibitory concentration (MIC) values
7. Eucaryotic cells protect Borrelia burgdorferi from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycin
8. An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to metronidazole
9. Lyme disease assay which detects killed Borrelia burgdorferi
10. Summary of notifiable diseases. United States, 1996
11. Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients
12. Penetration of endothelial cell monolayers by Borrelia burgdorferi
13. Ceftriaxone as effective therapy in refractory Lyme disease
14. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: A microdilution MIC method and time-kill studies
15. Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi
16. In vitro activity of vancomycin against the spirochete Borrelia burgdorferi
17. In vitro susceptibility testing of Borrelia burgdorferi by a dialysis culture method
18. In vitro activities of the everninomicin SCH 27899 and other newer antimicrobial agents against Borrelia burgdorferi
19. Cases of Lyme borreliosis resistant to conventional treatment: Improved symptoms with cephalosporin plus specific beta-lactamase inhibition
20. Roxithromycin in Lyme borreliosis: Discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans
21. Cefotaxime versus penicillin in the late stage of Lyme disease - Prospective, randomised therapeutic study
22. Pulsed high-dose cefotaxime therapy in refractory Lyme borreliosis
23. Serologically proven double infection with tick-borne encephalitis virus (TBEV) and Borrelia burgdorferi
24. Serologic evidence for tick-borne pathogens other than B. burgdorferi (TOBB) in Lyme borreliosis patients from midwestern Germany
25. A new colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances
26. Colorimetric in vitro susceptibility testing of penicillins, cephalosporines, macrolides, streptogramins, tetracyclines and aminoglycosides against Borrelia burgdorferi isolates
27. In vitro activity of quinolones against Borrelia burgdorferi
28. In vitro activity of mezlocilline, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin, and fusidic acid against Borrelia burgdorferi isolates
29. Colorimetric susceptibility testing of ABT-773 - A novel ketolide. Against 17 isolates of the Borrelia burgdorferi sensu lato complex
30. Antimicrobial susceptibility of Ehrlichia phagocytophila
31. Susceptibility of the Lyme disease spirochete to seven antimicrobial agents
32. Comparative in vitro and in vivo susceptibility of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents
33. Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis
34. In vitro activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites
35. Ketolide ABT- 773 is active against Toxoplasma gondii
36. Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi
37. Antibiotic susceptibility of the newly cultivated agent of human granulocytic ehrlichiosis: Promising activity of quinolones and rifamycins
38. In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents
39. Treatment resistant Lyme arthritis caused by Borrelia garinii
40. New chemotherapeutic approaches in the treatment of Lyme borreliosis
41. Intracellular localisation of Borrelia burgdorferi within human endothel cells
42. A cost-of-illness study of Lyme disease in the United States
43. Fulminant refractory Lyme disease
44. Evaluation of agents for use in medium for selective isolation of Lyme disease and relapsing fever Borrelia species
45. Surveillance for Lyme disease - United States, 1992-1998
46. Therapy and prognosis
47. Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease
48. In vitro susceptibility of B. burgdorferi, B. garinii and B. afzelii to 7 antimicrobial agents
49. Localization of Borrelia burgdorferi in murine Lyme borreliosis by electron microscopy
50. Proposal for the reliable culture of Borrelia burgdorferi from patients with chronic Lyme disease, even from those previously aggressively treated
51. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis
52. European Borrelia burgdorferi isolated from humans and ticks: Culture conditions and antibiotic susceptibility
53. In vitro and in vivo susceptibility of Borrelia burgdorferi
54. Comparative in vitro activity of the new macrolides against Borrelia burgdorferi
55. Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis
56. Culture of Borrelia burgdorferi on six solid media
57. Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis
58. Formation and cultivation of Borrelia burgdorferi spheroblast-L-form variants
59. Inactivation of diaminopyrimidines and sulfonamides in Barbour-Stoenner-Kelly medium for isolation of Borrelia burgdorferi
60. Antibiotics and increased temperature against Borrelia burgdorferi in vitro
61. In vitro activity of trimethoprim against Borrelia burgdorferi
62. Tick ecology and epidemiology
63. Treatment of refractory chronic Lyme arthritis with arthroscopic synovectomy
64. Lyme disease: A review of aspects of its immunology and immunopathogenesis
65. Esterases in serum-containing growth media counteract chloramphenicol acetyltrans-ferase activity in vitro
66. Treatment of the early manifestations of Lyme disease
67. Dialysis culture enables more accurate determination of MIC of benzylpenicillin for Borrelia burgdorferi than does conventional procedure
68. Dialysis culture for determination of MIC and MBC of benzylpenicillin against Borrelia burgdorferi
69. Principles of the diagnosis and antibiotic treatment of Lyme borreliosis
70. Penicillin behandling vid dermatitis atrophicans Herxheimer
71. The Lyme disease vaccine: Conception, development, and implementation
72. The penicillin treatment of acrodermatitis chronica atrophicans (Herxheimer)
73. Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis
74. The recombinant outer surface protein A (lipOspA) of Borrelia burgdorferi: A Lyme disease vaccine
75. The Erve virus: Possible mode of transmission and reservoir
76. Practice guidelines for the treatment of Lyme disease
77. Underreporting of Lyme disease